Journal articleClin Cancer Res2017
Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma.
- Journal
- Clin Cancer Res
- Published
- 4 October 2016
- Citations
- 66
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 6
- 11 Solid Tumor Therapeutics Program P30CA091842↗
- Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
- The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670↗
- COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY R01CA203890↗
- TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY R21CA182701↗
- IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA R37CA219697↗